Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pro-fibrotic factor expression refers to the increased production of molecules that promote fibrosis, a pathological process characterized by excessive deposition of extracellular matrix components. Key pro-fibrotic factors include TGF-β, CTGF, PAI-1, collagens, fibronectin, and P4HA3. These factors activate signaling pathways that lead to fibroblast proliferation, myofibroblast transdifferentiation, and enhanced ECM protein synthesis, resulting in tissue scarring and organ dysfunction. Targeting pro-fibrotic factor expression, particularly TGF-β signaling, is a major therapeutic strategy for treating fibrosing diseases.
Inhibition or modulation of TGF-β signaling and downstream pro-fibrotic pathways.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pro-fibrotic Factor Expression.